8-K: Lixte Biotech Restructures Orbit Capital Equity Deal

Lixte Biotechnology Holdings, Inc. completed a share exchange with Orbit Capital Inc., converting Series C Preferred Stock into common stock and a stake in its Liora subsidiary.

Summary

• Lixte Biotechnology Holdings, Inc. (PubCo) entered into a Share Exchange Agreement with Orbit Capital Inc. (Shareholder) on December 30, 2025.
• Orbit Capital exchanged all of its 2,700 shares of Lixte's Series C Preferred Stock.
• In return, Orbit Capital received 700,000 shares of Lixte's common stock, $0.0001 par value per share, and 200 ordinary shares of Liora Technologies Europe Ltd., representing 20% of Liora's outstanding securities.
• Following the exchange, all 2,700 Series C Preferred Stock shares were cancelled, and Lixte now holds 800 ordinary shares of Liora.
• The transaction is intended to qualify as a tax-free reorganization under Section 354 of the Internal Revenue Code of 1986, as amended.
• The issuance of common stock was made in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act of 1933 and/or Rule 506 of Regulation D.

Sentiment

Score: 5

Explanation: The filing describes a neutral corporate restructuring event. While it involves dilution of common stock and a partial divestment of a subsidiary, it also simplifies the capital structure by cancelling preferred shares. No explicit positive or negative financial performance is reported, leading to a neutral sentiment.

Positives

• Cancellation of all 2,700 Series C Preferred Stock shares simplifies the company's capital structure.
• The transaction is intended to qualify as a tax-free reorganization under Section 354 of the Internal Revenue Code for the parties involved.
• Lixte retains an 80% ownership stake in its subsidiary, Liora Technologies Europe Ltd.

Negatives

• Issuance of 700,000 common shares to Orbit Capital Inc. will result in dilution for existing common stockholders.
• Lixte's ownership in its wholly-owned subsidiary, Liora Technologies Europe Ltd., decreased from 100% to 80%.

Risks

• Investment in the Exchanged Shares involves a high degree of risk, as acknowledged by the Shareholder.
• Shareholder acknowledges the risk factors included in PubCo's most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q.
• Shareholder is in a financial position to hold the Exchanged Shares indefinitely and is able to bear the economic risk and withstand a complete loss of an investment in the Exchanged Shares.
• The Exchanged Shares are characterized as restricted securities and cannot be sold or transferred unless such resale is subsequently registered under the Securities Act or an exemption from such registration is available (e.g., Rule 144 or Regulation S).

Future Outlook

The filing primarily details a completed corporate finance transaction and does not provide explicit forward-looking statements or guidance regarding future financial performance, operational results, or strategic direction beyond the tax implications of the share exchange.

Management Comments

• The registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Industry Context

This transaction represents an internal capital restructuring and a partial divestiture of a subsidiary stake for Lixte Biotechnology Holdings, Inc. While not directly indicative of broader industry trends, such adjustments are common for biotechnology companies managing their equity structure, investor relationships, or optimizing their portfolio of early-stage assets.

Comparison to Industry Standards

• The filing does not provide sufficient operational or financial data to make specific comparisons to industry benchmarks or comparable companies/projects. It focuses on a specific corporate finance transaction rather than performance metrics.

Corporate Governance

Stakeholder Impact

• **Shareholders (Common Stock)**: Will experience dilution due to the issuance of 700,000 new common shares.
• **Shareholders (Series C Preferred Stock)**: Orbit Capital Inc., as the sole holder, converted its preferred shares into common stock and a direct stake in Liora, altering its investment profile.
• **Lixte Biotechnology Holdings, Inc.**: Simplifies its capital structure by eliminating Series C Preferred Stock and adjusts its ownership in the subsidiary Liora Technologies Europe Ltd.

Next Steps

• The parties involved will execute and deliver such additional documents, instruments, conveyances, and assurances as may be reasonably required to carry out the provisions of the agreement.
• The Shareholder (Orbit Capital Inc.) may not make any disposition of the Exchanged Shares unless a registration statement under the Securities Act is in effect, an exemption from registration is available (e.g., Rule 144 or Regulation S), or an opinion of counsel, reasonably satisfactory to PubCo, is furnished.

Key Dates

Recommendation

The filing details a corporate restructuring that involves both dilution of common stock and a partial divestment of a subsidiary stake, balanced by the simplification of the capital structure through the cancellation of preferred shares. Without additional financial or operational context, the immediate impact on valuation is mixed. Investors should hold and await further clarity on the strategic rationale and financial implications of this restructuring, particularly regarding Liora's future prospects and the overall capital allocation strategy.

Keywords

Lixte Biotechnology, Orbit Capital, Share Exchange, Series C Preferred Stock, Common Stock, Liora Technologies, Equity Restructuring, SEC Filing, 8-K, Biotechnology, Corporate Governance, Capital Structure